Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC
By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD
Posted: August 19, 2020
Immune checkpoint inhibitors (CPIs) have revolutionized the...
KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease
By Kara Nyberg, PhD
Posted: August 2018
The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint...
Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou
Posted: December 2018
In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical...
Immunotherapy Adverse-Event Treatment Resource Guide
The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline...
Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to...
By Ross Soo, MB BS, PhD, FRACP
Posted: December 2018
The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs)...
Management of Immunotherapy Toxicity in NSCLC
By Beth Eaby-Sandy, MSN, CRNP
Posted: February 2018
When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was...
Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC
By Mariano Provencio-Pulla, MD, PhD
Posted: December 2018
Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of...
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC
By Hossein Borghaei, MS, DO
Posted: February 2018
The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For...
IMpower133: Finally Moving the Needle in SCLC
By Stephen V. Liu, MD
Posted: March 1, 2019
The addition of atezolizumab to standard chemotherapy for extensive-stage SCLC achieved what, for decades, had been beyond...
PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016
By Erik J. MacLaren, PhD
Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting...
